Researchers have used TissueGnostics' advanced imaging and analysis tools to detect and quantify two cell types: the PD-1+ regulatory T cells (Treg)/PD-1+CD8+ cytotoxic T cells (CTL) ratio and ...

High numbers of regulatory T cells (red) — seen here interacting with antigen-presenting cells (blue) — are usually associated with poorer outcomes in cancer. A new MSK study, however, found that a ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Add Yahoo as a preferred source to see more of our stories on Google. Treg cells have been thrust into the limelight thanks to the Nobel Prize-winning work of a team of researchers from the U.S. and ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory ...

MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data from the non-pivotal dose-confirmation ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system’s ability to fight against a tumor. Colorectal cancer, however ...